BioSpace News Archive

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced that on October 31, 2019, the Company granted stock options and restricted stock units to three new employees of the Company.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 90,000 ordinary shares of Nabriva Therapeutics as inducements to 3 newly-hired employees.

Y-mAbs Therapeutics, Inc. announced the closing of its public offering of 5,134,750 shares of its common stock, at a public offering price of $28.00 per share, which includes the exercise in full of the underwriters’ option to purchase 669,750 additional shares of common stock.

Today Aetion, the health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies, announced a new integrated solution focused on advancing the use of real-world evidence for small and mid-sized biopharmaceutical companies.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2019.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a late-breaking oral presentation and two posters on KORSUVA™ (CR845/difelikefalin) Injection will be presented at Kidney Week 2019, the American Society of Nephrology’s Annual Meeting, to be held November 5-10, 2019, in Washington, DC.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has begun a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP).

Seneca Biopharma, Inc., (NASDAQ: SCNA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, and Jiangsu QYuns Therapeutics Co., Ltd., a China-based company focused on monoclonal antibody therapeutics, jointly announce development plans for a joint pipeline of products for the treatment of immunological diseases, at the 7th China Renaissance Healthcare and Life Science Leadership Summit.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies to treat life-threatening conditions, announced the first patient enrollment in the company-sponsored Ticagrelor CytoSorb® Hemoadsorption (TISORB) study in the United Kingdom (U.K.).

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2019